Arkolith/Insider Trading/BNTC/Form 4

Averill Master Fund, Ltd.

Director, 10% OwnerBenitec Biopharma Inc. (BNTC) · full profile →Form 4 · filed Sep 30, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
10
5 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 26, 2024Option exercise(X)1.2M—$07.9M
Sep 26, 2024Option exercise(X)576K$3.86$2.2M797K
Sep 26, 2024Option exercise(X)148K—$0946K
Sep 26, 2024Option exercise(X)588K$1.93$1.1M2.1M
Sep 26, 2024Option exercise(X)4.6M$3.86$17.8M6.7M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 26, 2024Option exercise(X)148K—$0428K
Sep 26, 2024Option exercise(X)1.2M—$03.4M
Sep 26, 2024Option exercise(X)4.6M—$00
Sep 26, 2024Option exercise(X)10.0M—$00
Sep 26, 2024Option exercise(X)576K—$00

Transaction Codes

X
Exercise of in-the-money derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899140-24-001042) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML